On the Prohibition of Conlficts of Interest in Pharmaceutical Regulation: Precautionary Limits and Permissive Challenges. A Commentray on Sismondo (66:9, 2008, 1909-14) and O'Donovan and Lexchin  

Oleh:

Abraham, John

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Social Science & Medicine (www.elsevier.com/locate/sosscimed) vol. 70 no. 5 (Mar. 2010), page 648-651.
Topik: Ireland; United Kingdom; European Union (EU); Conflict of Interest; Drug Regulation; Risk Management

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: SS53 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Conflict of Interest is a complex issue theoretically, empirically and with reference to pragmatic policy-making. In his considerations of pharmaceutical industry funding if clinical trials, Sismondo argues that the term 'conflict of interest' is misleading because it 'suggests that researchers act inappropriately to further their own interests', and 'it is not clear that medical researchers often have material interests in particular results' (Sismondo, 2008, p. 1910). However, in this issue of Social Science & Medicine, Lexchin and O'Donovan (2010) are right to employ the term 'conflicts of interest' because it has fundamental analytical value in their review to the approach of three European Union drug regulatory bodies.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali